



Servier in Diabetes

- Factsheet -

About Servier

- Servier is France's leading independent pharmaceutical company and the second largest French drug company worldwide. Research at Servier is focused on cardiovascular disease, neuropsychiatric disease, osteoporosis, cancer and metabolic diseases – of which diabetes is a major priority.

Diabetes commitment

- Servier has been committed to optimization of the treatment of type 2 diabetes for over 30 years, through the discovery of original antidiabetic agents and numerous activities promoting research and education.
- A total of 15% of the company's global turnover per therapeutic class is composed of diabetes drugs.
- The key drug in Servier's diabetes portfolio is Diamicon MR, which is indicated for the treatment of adults with type 2 diabetes. Diamicon MR, a modified-release version of the sulfonylurea drug gliclazide, is the company's second leading product and accounts for 14% of Servier's total global turnover.

Servier – taking diabetes therapy forward

- Servier is at the cutting edge of treatments for type 2 diabetes and is a leading international force in the diabetes arena thanks to its proven combination of internal and external research and strategic alliances.
- For over 25 years, the company has devoted great efforts in France, as well as internationally, to supporting and training doctors, and educating patients on diabetes.

- To treat the diabetes of the 21st century, Servier is looking for more appropriate treatments. Within the field of type 2 diabetes in particular, Servier is working towards two major treatment goals:
 - To restore and maintain an appropriate secretion of insulin
 - To protect the blood vessels – this is an essential element of treatment as it constitutes the most serious aspect of the diabetes disease
- As a research-based pharmaceutical company, Servier has an established and ongoing commitment to R&D in type 2 diabetes. In testament to this, the Servier diabetes products currently produced have originated from the company's *own* research efforts.

An active diabetes presence

- As a key part of its commitment to diabetes, Servier maintains long-term partnerships with leading diabetes associations all over the world.
- In addition to a large number of affiliations at national and regional levels, Servier is a long-term contributor to, and platinum corporate partner of, the International Diabetes Federation (IDF). The company is also a gold member of the European Association for the Study of Diabetes (EASD).
- As well as maintaining fruitful diabetes partnerships, Servier is the long-term sponsor of a number of important organizations in the world of diabetes. These include:
 - * *The Diabetes Education Study Group (DESG) of the EASD*
 Together with the DESG, Servier is involved in organizing interactive seminars and workshops at key diabetes events – efforts which have already brought together 4000 diabetes-focused physicians and nurses from all over the world. This partnership also undertakes the production and distribution of educational materials for doctors and patients alike. Versions in several languages of the popular series 'Patient Education Basics' and the 'DESG Teaching Letters' are distributed world-wide, helping both doctors and patients to better manage the complexities of life with diabetes.
 - * *The Mediterranean Group for the Study of Diabetes (MGSD)*
 For over 12 years, Servier has been cooperating with the MGSD in its efforts to promote the exchange of diabetes experience, research and knowledge between Mediterranean countries. This is achieved via a mix of international meetings, media news publications

and the development of fellowships and travel grants for young physicians in order to promote training and expertise in diabetes throughout Southern Mediterranean countries.

Other prestigious diabetes projects sponsored by Servier include:

* *The Morgagni Prize*

To encourage innovative research in diabetes and related metabolic disorders, Servier has sponsored the Morgagni Prize for outstanding European research in metabolism since 1998.

* *The Robert Turner Professorship in Diabetic Medicine*

As a measure of the company's commitment to diabetes research now and in the future, Servier recently endowed a new diabetes chair at Oxford: the Robert Turner Professorship in Diabetic Medicine. This project promises to attract an outstanding international figure in diabetes research to the new \$14.5 million Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM). Currently under construction, the OCDEM will be the first in the world to truly integrate basic and clinical research, clinical care and patient education in hormone-related and metabolic diseases such as diabetes. As such, it promises to become a pivotal focus for future international research in diabetology.

Source:
Servier.com